Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP13512 Dose-Response in RLS
NCT01332305Phase 2Completed
- Sponsor
- XenoPort, Inc.
- Start
- Jan 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gabapentin enacarbil in restless legs syndrome (RLS), sponsored by XenoPort, Inc.. Started Jan 2007; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT01332305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332305.